手法を比較

	多発性硬化症歩行スケール-12 (MSWS-12)	Modified Rankin Scale (mRS)	脳卒中特異的生活の質スケール (SS-QoL)
分野	神経学	神経学	神経学
系統	Process / pipeline	Process / pipeline	Process / pipeline
提唱年	2003	1988	1999
提唱者	Jeremy C. Hobart, University of Plymouth	Rankin scale original (Rankin, 1957); modified version by van Swieten et al.	Lee S. Williams, Indiana University
種類	Self-report questionnaire	Clinician-rated ordinal scale	Self-report questionnaire
原典	Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2003). Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology, 60(1), 31-36.	van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19(5), 604-607.	Williams, L. S., Weinberger, M., Harris, L. E., Clark, D. O., & Biller, J. (1999). Development of a Stroke-Specific Quality of Life Scale. Stroke, 30(7), 1362-1369.
別名	MS Walking Scale-12, MSWS	mRS, Rankin Scale, Modified Rankin	Stroke-Specific QoL, SS-QOL
関連	3	4	4
概要	The MSWS-12 is a brief, patient-reported outcome measure specifically designed to assess the impact of multiple sclerosis on walking ability and limitation. Developed by Hobart and colleagues in 2003, this 12-item scale captures both the physical difficulty and functional consequences of MS-related gait impairment. It is highly responsive to change and widely used in MS clinical trials and practice as a primary outcome measure for assessing intervention effects on mobility.	The Modified Rankin Scale is a simple 0-6 ordinal measure of global disability or dependency in patients with stroke and other neurological conditions. Originally developed by Rankin in 1957 and modified by van Swieten and colleagues in 1988, it remains the most widely used global disability outcome in stroke clinical trials and clinical practice. Its simplicity, brevity, and strong prognostic association make it the gold standard for acute stroke outcome measurement and is mandated as a primary endpoint in virtually all stroke therapeutic trials.	The SS-QoL is a disease-specific quality-of-life instrument designed to capture the multidimensional impact of stroke on survivors' functional and emotional well-being. Developed by Williams and colleagues in 1999, this 49-item scale addresses stroke-specific concerns including language, cognition, mobility, and emotional functioning. It is a gold-standard instrument for stroke outcome research and routine clinical monitoring of post-stroke recovery.